Prophylaxis in children with hemophilia: is it the optimal treatment?
Lusher
J M
JM
Children's Hospital of Michigan, Detroit 48201, USA.
D000917:Antibody Formation; D002648:Child; D003362:Cost-Benefit Analysis; D005164:Factor IX / Q000191:economics / Q000627:therapeutic use*; D005169:Factor VIII / Q000191:economics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013548:Sweden
D005169:Factor VIII; D005164:Factor IX